Condom Use and the Prevention of Genital Herpes Acquisition

Herpes

Volumn 9, Issue 1, 2002, Pages 10-14

  Casper, Corey ^a   Wald, Anna ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Condom; Genital herpes disease prevention; Herpes simplex virus type 2 (HSV 2)

Indexed keywords

4 DIISOBUTYLPHENOXYPOLYETHOXYETHANOL; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; COPPER; HERPES SIMPLEX VACCINE; LATEX; LUBRICATING AGENT; NONOXINOL 9; ORAL CONTRACEPTIVE AGENT; RECOMBINANT VACCINE; SPERMICIDAL AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; CONDOM; CORRELATION ANALYSIS; DRUG UTILIZATION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; MORBIDITY; MORTALITY; NEWBORN INFECTION; OUTCOMES RESEARCH; PATIENT EDUCATION; PREGNANCY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK FACTOR; SEROPREVALENCE; SEX DIFFERENCE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; VIRUS SHEDDING; VIRUS TRANSMISSION; DEVELOPING COUNTRY; DISEASE TRANSMISSION; INCIDENCE; PHYSIOLOGY; PREVALENCE; STANDARD; STATISTICS;

HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

CLINICAL TRIALS; CONDOMS; DEVELOPING COUNTRIES; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; INCIDENCE; PREVALENCE;

EID: 0036550343     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-1111.
2. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847-854.
3. Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 2001;8:46-49.
4. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176:766-770.
5. Hennessey KA, Giorgi JV, Kaplan AH, Visscher BR, Gange S, Margolick JB et al. AIDS onset at high CD4+ cell levels is associated with high HIV load. AIDS Res Hum Retroviruses 2000;16:103-107.
6. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52.
7. Corey L. Herpes simplex type 2 infection in the developing world: is it time to address this disease? Sex Transm Dis 2000;27:30-31.
8. Cusini M, Cusan M, Parolin C, Scioccati L, Decleva I, Mengoli C et al. Seroprevalence of herpes simplex virus type 2 infection among attendees of a sexually transmitted disease clinic in Italy. Italian Herpes Forum. Sex Transm Dis 2000;27:292-295.
9. Butler T, Donovan B, Taylor J, Cunningham AL, Mindel A, Levy M et al. Herpes simplex virus type 2 in prisoners, New South Wales, Australia. Int J STD AIDS 2000;11:743-747.
10. Perkins NL, Coughlan EP, Franklin RA, Reid MR, Taylor J. Seroprevalence of herpes simplex virus type 2 antibodies in New Zealand sexual health clinic patients. N Z Med J 1996;109:402-405.
11. McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Ley C et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999;180:1459-1465.
12. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990;69:19-36.
13. Janier M, Lassau F, Bloch J, Spindler E, Morel P, Gerard P et al. Seroprevalence of herpes simplex virus type 2 antibodies in an STD clinic in Paris. Int J STD AIDS 1999;10:522-526.
14. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMI 1994;309:1325-1329.
15. Wagner HU, Van Dyck E, Roggen E, Nunn AJ, Kamali A, Schmid DS et al. Seroprevalence and incidence of sexually transmitted diseases in a rural Ugandan population. Int J STD AIDS 1994;5:332-337.
16. Hernandez-Giron C, Uribe-Salas F, Conde-Gonzalez C, Cruz-Valdez A, Juarez-Figueroa L, Uribe-Zuniga P et al. Seroprevalence of various viruses and sociodemographic characteristics of women seeking HIV screening. Rev Invest Clin 1997;49:5-13.
17. Da Rosa-Santos OL, Goncalves Da Silva A, Pereira AC, Jr. Herpes simplex virus type 2 in Brazil: sero-epidemiologic survey. Int J Dermatol 1996;35:794-796.
18. Berry J, Crowley T, Hormer P, Harvey I. Orogential sex as a risk factor for the development of primary genital herpes; a case-control study (abstract). 12th Meeting of the International Society of Sexually Transmitted Disease Research (ISSTDR), Seville, Spain, 1997.
19. Lafferty WE, Downey L, Celum C, Wald A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and preventi on. J Infect Dis 2000;181:1454-1457.
20. Corey L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA 2000;283:791-794.
21. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
22. Bernstein DI, Harrison CJ, Jenski LJ, Myers MG, Stanberry LR. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy. J Immunol 1991:146:3571-3577.
23. Bernstein DI, Ashley RL, Stanberry LR, Myers MG. Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines. J Clin Microbiol 1990;28:11-15.
24. Bernstein DI. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 2000;18:1351-1358.
25. Bernstein DI, Tepe ER, Mester JC, Arnold RL, Stanberry LR, Higgins T. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection. Vaccine 1999;17:1964-1969.
26. Bernstein DI, Miller RL, Harrison CJ. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis 1993;167:731-735.
27. Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996;14:1230-1234.
28. Harrison CJ, Miller RL, Bernstein DI. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001;19:1820-1826.
29. Milligan GN, Bernstein DI. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology 1995;206:234-241.
30. Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine 1999;18:875-883.
31. Myers MG, Bernstein DI, Harrison CJ, Stanberry LR. Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs. Antiviral Res 1988;10:83-88.
32. Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis 2000;182:1304-1310.
33. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155:914-920.
34. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM, Jr et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999;282:331-340.
35. Mertz GJ, Ashley R, Burke RL, Benedetti J, Critchlow C, Jones CC et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990;161:653-660.
36. Spruance S. Gender-specific efficacy of a prophylactic SBAS4-adjuvanted gD2 subunit vaccine against genital herpes disease (GHD): results of two clinical efficacy trials (abstract). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.
37. Handsfield HH, Stone KM, Wasserheit JN. Prevention agenda for genital herpes. Sex Transm Dis 1999;26:228-231.
38. Centers for Disease Control, Division of Sexually Transmitted Diseases. Factsheet on Genital Herpes. Available at: www.cdc.gov/nchstp/dstd/Fact_Sheets/facts_Genital_Herpes.htm
39. National Institute of Allergy and Infectious Disease. Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention. Herdon, VA, USA, 2001.
40. Corey L: Herpes simplex virus. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th edn (Mandell GL, Douglas RG, Bennett JE, Dolin R, eds). Philadelphia: Churchill Livingstone, 2000; pp1564-1580.
41. Kish LS, McMahon JT, Bergfeld WF, Pelachyk JM. An ancient method and a modem scourge: the condom as a barrier against herpes. J Am Acad Dermatol 1983;9:769-770.
42. McNiell ET, Gilmore CE, Finger WR, Lewis JH, Schellstede WP. The Latex Condom: Recent Advances, Future Directions. Research Triangle Park, NC: Family Health International, 1999.
43. Voeller B. Gas, dye, and viral transport through polyurethane condoms. JAMA 1991;266:2986-2987.
44. Judson FN, Ehret JM, Bodin GF, Levin MJ, Rietmeijer CA. In vitro evaluations of condoms with and without nonoxynol 9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989;16:51-56.
45. Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990;17:110-112.
46. Conant MA, Spicer DW, Smith CD. Herpes simplex virus transmission: condom studies. Sex Transm Dis 1984;11:94-95.
47. Singh B, Posti B, Cutler JC. Virucidal effect of certain chemical contraceptives on type 2 herpesvirus. Am J Obstet Gynecol 1976;126:422-425.
48. Postic B, Singh B, Squeglia NL, Guevarra LO. Inactivation of clinical isolates of Herpesvirus hominis, types 1 and 2, by chemical contraceptives. Sex Transm Dis 1978;5:22-24.
49. O'Brien FP. Work-related fear of AIDS and social-desirability response bias. Psychol Rep 1989;65:371-378.
50. Latkin CA, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV seropositive injection drug users. Addiction 1998;93:1191-1197.
51. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993;88:517-526.
52. Zenilman JM, Weisman CS, Rompalo AM, Ellish N, Upchurch DM, Hook EW, 3rd et al. Condom use to prevent incident STDs: the validity of self-reported condom use. Sex Transm Dis 1995;22:15-21.
53. Austin H, Macaluso M, Nahmias A, Lee FK, Kelaghan J, Fleenor M et al. Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Sex Transm Dis 1999;26:329-334.
54. Lowhagen GB, Tunback P, Andersson K, Johannisson G. Recurrent genital herpes in a population attending a clinic for sexually transmitted diseases. Acta Derm Venereol 2001;81:35-37.
55. Wald A, Koutsky L, Ashley RL, Corey L. Genital herpes in a primary care clinic. Demographic and sexual correlates of herpes simplex type 2 infections. Sex Transm Dis 1997;24:149-155.
56. Huerta K, Berkelhamer S, Klein J, Ammerman S, Chang J, Prober CG. Epidemiology of herpes simplex virus type 2 infections in a high-risk adolescent population. J Adolesc Health 1996;18:384-386.
57. Sucato G, Celum C, Dithmer D, Ashley R, Wald A. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. Pediatr Infect Dis J 2001;20:422-426.
58. Smith JS, Herrero R, Munoz N, Eluf-Neto J, Ngelangel C, Bosch FX et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis 2001;28:187-194.
59. Oberle MW, Rosero-Bixby L, Lee FK, Sanchez-Braverman M, Nahmias AJ, Guinan ME. Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. Am J Trop Med Hyg 1989;41:224-229.
60. Dobbins JG, Mastro TD, Nopkesorn T, Sangkharomya S, Limpakarnjanarat K, Weniger BG et al. Herpes in the time of AIDS: a comparison of the epidemiology of HIV-1 and HSV-2 in young men in northern Thailand. Sex Transm Dis 1999;26:67-74.
61. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
62. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993;167:942-946.
63. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-3106.
64. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991;324:450-454.
65. Prober CG, Hensleigh PA, Boucher FD, Yasukawa LL, Au DS, Arvin AM. Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med 1988;318:887-891.
66. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509-516.
67. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247-1252.
68. Toltzis P, Stephens RC, Adkins I, Lombardi E, Swami S, Snell A et al. Human immunodeficiency virus (HIV)-related risk-taking behaviors in women attending inner-city prenatal clinics in the mid-west. J Perinatol 1999;19:483-487.
69. Wilson TE, Minkoff H, McCalla S, Petterkin C, Jaccard J. The relationship between pregnancy and sexual risk taking. Am J Obstet Gynecol 1996;174:1033-1036.
70. Crosby RA, DiClemente RJ, Wingood GM, Sionean C, Cobb BK, Harrington K et al. Correlates of using dual methods for sexually transmitted diseases and pregnancy prevention among high-risk African-American female teens. J Adolesc Health 2001;28:410-414.
71. Gregson J, Kirkman R. Double Dutch: looking at the usage of combined pill plus condom in girls under 25. Eur J Contracept Reprod Health Care 1999;4:45-48.
72. Roye CF. Condom use by Hispanic and African-American adolescent girls who use hormonal contraception. J A dolesc Health 1998;23:205-211.
73. Stanton BF, Li X, Galbraith J, Feigelman S, Kaljee L. Sexually transmitted diseases, human immunodeficiency virus, and pregnancy prevention. Combined contraceptive practices among urban African-American early adolescents. Arch Pediatr Adolesc Med 1996;150:17-24.
74. Humphries HO, Bauman KE. Condom use by Norplant users at risk for sexually transmitted diseases. Sex Transm Dis 1994;21:217-219.
75. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL, Jr et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001;185:380-385.